| 1. | nomaam4565 | |
| 2. | pierceton | |
| 3. | dianamoonblade1 | |
| 4. | SugarDaddy | |
| 5. | nshsn8vjkdpyvqf |
Top Board Researchers
These are the top researchers based on quality of posts as voted by board members. Typically they know their stuff and are a great
way to catch up on what the company is all about.
HOW DO I BECOME ONE?
Just do great research! As other members approve of your posts, you earn points that move you up the ranks.| 1. | dianamoonblade1 02/05/2018 Granted orphan drug designation by the FDA for Imbruvica for the treatment of gastric cancer, including gast… |
| 2. | SugarDaddy 10/18/2017 {Image} |
| 3. | dianamoonblade1 03/27/2018 Chicago jury has ordered AbbVie to pay a man $3M who claimed the company misrepresented the risks of its tes… |
| 4. | pierceton 01/26/2018 AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results |
| 5. | dianamoonblade1 02/18/2018 AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn's Disease at 52 Weeks |
| 6. | SugarDaddy 07/24/2018 Receives FDA approval of ORILISSA (elagolix) for the management of moderate to severe pain |
| 7. | nomaam4565 01/29/2018 $144 PT |
| 8. | pierceton 02/18/2018 AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting |
| 9. | SugarDaddy 04/05/2018 AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Samsung Bioepis |
| 10. | pierceton 01/26/2018 Sees FY18 EPS of $7.33-7.43 from $6.37-6.57 |
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW
AbbVie Inc.
- ABBV
- Public Stock Message Board
Filtering by:
-
To use your chart in a post, click the
icon above the chart. From there you can get the chart link or download the image.